AuntMinnie Newsletter
Web version


DBT Shown Superior to DM

A recently published Academic Radiology study added to the body of evidence showing DBT is more effective and efficient than 2D mammography alone. The study analyzed outcomes associated with more than 190,000 DBT exams and more than 130,000 DM exams over a two-year period at 39 imaging facilities across two healthcare systems.

Among its findings, the study solidified DBT as the gold standard of care for breast cancer screening.

Diagnostic Workflow is Streamlined with DBT

Among women recalled, those screened with DBT had streamlined diagnostic workflow:

  • Less diagnostic mammography
  • Faster time to biopsy
  • Faster time to final diagnosis

Benefits of Full DBT Conversion

DBT recall rates were lower at sites that predominantly perform DBT screening (8.02%), compared to facilities that perform a mix of DM alone and DBT screening (10.43%).

DBT Outperforms DM for All Breast Density Categories

Recall rates were lower and cancer detection rates were higher for DBT compared to DM across all breast density categories.


The New Standard for Breast Cancer Screening

Not only is DBT the indisputable standard for breast cancer screening, the Hologic 3D Mammography™ exam is the only mammogram proven to be superior for women of all ages and breast densities, including those with dense breasts.i, ii In fact, Hologic's 3Dimensions™ mammography system is the fastest, highest resolution breast tomosynthesis system capable of delivering a more comfortable mammogram.iii, iv The new system completely transforms the patient experience, improving comfort without sacrificing image quality, exam time, dose or workflow.iv Not only is the system clinically proven to deliver a more comfortable mammogram, the Genius™ 3D Mammography™ exam is also proven to detect 20-65% more invasive cancers than 2d alone.v

Discover how the new Hologic 3Dimensions™ mammography system and imaging portfolio can take your practice to the next level.

    Learn More    

  Sheryl Crow Continues Support for Genius™ Exams

Facebook post photo of Sherly Crow, nurse and Genius 3D device

Product Spotlight

Fluoroscan® InSight™ Mini C-arm

Devised to enable physicians with general fluoroscopic visualization of a patient, the Fluoroscan® InSight™ Mini C-arm provides diversified imaging options, an enhanced 24" HD touchscreen interface, and more flexible storage and

"I could not image my orthopedic practice without my Fluoroscan. It is used a dozen times or more every day and not only speeds up my clinic by avoiding the wait for X-ray, but I also get the exact image I need, quickly and efficiently, allowing us to do a better job." - Noah D. Weiss, MD, Sutter Surgery Center Novato

The latest Hologic product to embody the company's commitment to servicing the field of skeletal care, the system offers a variety of features designed to provide orthopedists, podiatrists and clinicians with a mobile solution that can lower dose by up to 50% while still maintaining exceptional image quality.vii

Fluoroscan InSight Mini C-arm

Top Industry Headlines and Research


Taking the Mystery Out of Breast Density

There is a concerning lack of awareness surrounding breast density, but recent legislative efforts, research and technological advancements are putting breast density at the forefront of national conversation to enable earlier access to treatment. Dr. Emily Conant, chief of breast imaging in the University of Pennsylvania's department of radiology, was quoted in the article explaining she believes women should be informed about their breast density and the pros and cons of supplemental screening.

Study Confirms Denser Breasts Are More Prone to Cancer

A new Radiology study out of Norway found automated breast density measurement tools can accurately categorize tissue density, and women with dense breast tissue have higher odds of both screen-detected and interval breast cancer, suggesting additional screening might be beneficial. An accompanying editorial written by Dr. Liane Philpotts, chief of breast imaging at the Yale School of Medicine, mentions about half of American women who are screened for breast cancer have dense breast tissue, which can only be determined by a mammogram.

Hologic acquires Faxitron Bioptics for $85 million    

States' DBT Insurance and Density Reporting Legislation

New Hampshire and Oklahoma will become the 15th and 16th states respectively to require insurer coverage of digital breast tomosynthesis. Additionally, Illinois will become the 36th state to require breast density notifications in patient-facing mammography reports.


Hologic Education Programs & Events

The Hologic-supported CME accredited seminars listed here are conducted by leading experts using the specific technology, as noted, in a screening and diagnostic practice. Locations/dates are subject to change. The seminars range from workshops to full, eight-hour training sessions. For more information and to register, please access the links below.

Live Courses

Breast MR with Guided Biopsy
September 17-18
November 12-13
Reston, VA

22nd Annual Duluth Breast Imaging Conference
September 28-29
Duluth, MN

Breast Imaging Boot Camp with Tomosynthesis
November 15-17
Reston, VA

Additional Medical Education Opportunities

Breast Screening

New Innovations in Breast Imaging
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Linda N. Greer, MD

3D Imaging with Synthesized 2D Images: Making the Transition from C-View to Intelligent 2D Imaging
Presenter: Andrew Smith, MD

Talking Sense About Breast Density: A Conversation with a Radiologist & a Gynecologist
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenters: DaCarla M. Albright, MD; Emily F. Conant, MD; and Moderator, Nancy M. Cappello, MD

Digital Breast Tomosynthesis Video Series
1.0 AMA PRA Category 1 Credit Each
Presenters: Elizabeth A. Rafferty, MD, and Sarah M. Friedewald, MD
- Breast Tomosynthesis: Current State of the Art
- Literature Review: Digital Breast Tomosynthesis
- Breast Tomosynthesis: Approach to the Diagnostic Evaluation
- Implementation and Clinical Application of Digital Breast Tomosynthesis
- Current Screening Guidelines – Can Tomosynthesis Shift the Equation?

Contrast-enhanced Mammography in Clinical Practice
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Daniela Bernardi, MD

Contrast-enhanced Mammography: Early Experience
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Bhavika K. Patel, MD

Synthesized 2D Mammography + Breast Tomosynthesis
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Emily F. Conant, MD

Low Dose 3D Mammography Imaging with C-View Software Training
Non-CME, hands-on, case-based training for radiologists
Presenters: Linda R.N. Greer, MD, and Andrew Smith, PhD

Advancements in 3D Mammography Technology for Technologists
1.0 ARRT Category A Credit
Presenter: Marcy Adcox, RT R M

Introduction to Breast Tomosynthesis for Technologists
1.0 ARRT Category A Credit
Presenter: Marcy Adcox, RT R M

I-View Software for Contrast-enhanced 2D Imaging
1.0 ARRT Category A Credit
Presenter: Marcy Adcox, RT R M

Localization Using Tomosynthesis: Tips for Accurately Localizing Lesions
Presenter: Linda Greer, MD

Breast Interventional

Affirm® Prone Biopsy System Education Experience
Presenter: Terri Gizienski, MD
- Module 1: Microcalcifications
- Module 2: Architectural Distortions
- Module 3: Tomo Only Findings
- Module 4: Challenging Cases

Clinical Use of 3D Image-guided Prone & Upright Breast Biopsy
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Alejandro Tejerina, MD

3D Image-guided Prone Breast Biopsy: Initial Clinical Experience
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Debbie Lee Bennett, MD


DXA University
DXA University has been designed to provide education, background and resources with different levels and content durations. The modules are presented by Dr. Jacob Wilson and are non-CME.

- Module 1: DXA University:

Overview why DXA is so important for today's clinicians and athletes.

- Module 2: DXA-101:

Introduction to the device specially designed to provide accurate assessments of an athlete's complete body composition.

- Module 3: DXA-201:

Pros and cons of different body composition methods available today to help make an educated decision around which method for assessment is right for you, your practice, your personal aspirations and human performance goals.

- Module 4: DXA-301:

Review DXA reporting to understand the different components of the report and benefits.

Expanding Role of DXA in Patient Health and Human Performance
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: John Shepherd, MD

Visceral Fat: The Invisible Health Risk
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Vyvyane Loh, MD

Osteoporosis Update 2015: It's All About the Fractures
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Ethel S. Siris, MD

Technologist's DXA 101 - The Basics of Bone Densitometry
1.0 AMA PRA Category 1 Credit / 1.0 ARRT Category A Credit
Presenter: Debra Burnham, BS, RT R M BD

Understanding Body Composition Assessment with Visceral Fat
.5 ARRT Category A Credit
Presenter: Nancy Fagan, RT R M BD CBDT


Hologic, 3D, 3D Mammography, 3Dimensions, Affirm, C-View, Dimensions, Fluoroscan, Genius, I-View, InSight, Intelligent 2D, The Science of Sure and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the U.S. and/or other countries. All other trademark, registered trademarks and product names are the property of their respective owners. This information is intended for medical professionals in the U.S. and other markets, and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, visit

©2018 Hologic, Inc., 250 Campus Drive, Marlborough, MA 01752 USA. Tel: 1.508.263.2900

*Compared to 2D alone
i FDA submissions P080003, P080003/S001,P080003/S004, P080003/S005
ii Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507.
iii Data on file and from public sources, 2017.
iv Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00119 Rev 003 (2017).
v Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
vi 510(k) K160131 retrieved on Jan 3 2018 from
vii Data based on simulated use workflow survey with 6 clinicians. (2017)

 Do not reply to this email as it was sent from an unmonitored account.
Unsubscribe from the Breaking News.
Reset your password.
Contact support. Privacy Policy
Email sent to: ., 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA - (520) 298-1000